Please login to the form below
Bristol Myers Squibb
This page shows the latest Bristol Myers Squibb news and features for those working in and with pharma, biotech and healthcare.
Bristol Myers Squibb and GentiBio in $1.9bn deal to develop IBD therapies
Bristol Myers Squibb (BMS) and GentiBio have announced a multi-year partnership to develop new regulatory T-cell (Treg) therapies to re-establish immune tolerance and repair tissue in patients living
Latest news
-
BMS and 2seventy bio announce positive results for multiple myeloma treatment
Bristol Myers Squibb (BMS) and 2seventy bio – a spin-out of bluebird bio – have announced positive phase 3 trial top-line results for Abecma (idecabtagene vicleucel) as a treatment for relapsed
-
Bristol Myers Squibb’s Opdualag approved by CHMP for melanoma
The Committee for Medicinal Products for Human Use (CHMP) branch of the European Medicines Agency (EMA) has recommended approval of the fixed-dose of Bristol Myers Squibb’s (BMS) Opdualag – a
-
Bristol Myers Squibb launches initiative to ensure disability diversity in clinical trials
Bristol Myers Squibb (BMS) has launched the Disability Diversity in Clinical Trials (DDiCT) initiative to ensure equal access to clinical trials, ensuring all patient groups are ‘reflective of the real-world
-
Bristol Myers Squibb announces NICE recommendation for Opdivo plus Yervoy to treat unresectable malignant pleural mesothelioma
Bristol Myers Squibb has announced that the National Institute of Health and Care Excellence (NICE) has recommended the combination of Opdivo (nivolumab) plus Yervoy (ipilimumab) for the first-line treatment of
-
Bristol Myers Squibb’s Opdivo given NICE recommendation for urothelial cancer treatment
The National Institute for Health and Care Excellence (NICE) has recommended Bristol Myers Squibb’s (BMS) Opdivo (nivolumab) to treat adult patients with muscle invasive urothelial carcinoma (MIUC).
More from news
Approximately 195 fully matching, plus 946 partially matching documents found.
Latest Intelligence
-
Why female mentorship is so powerful in pharma
Catherine Owen(pictured) is Senior Vice President of Major Markets at Bristol Myers Squibb.
-
Keeping up with the developing regulatory requirements for gene and cell therapies
Bristol Myers Squibb and bluebird bio’s idecabtagene vicleucel CAR-T therapy further emphasise this point.
-
Sourcing R&D innovation: why pharma companies need to evolve their business models
and. CAR-T therapies. Gilead’s acquisition of Kite Pharma and Bristol-Myers Squibb’s acquisition of Juno Therapeutics, as well as the merger and acquisition agreements between Novartis/Spark and
-
Switzerland: a life sciences hub
Celgene, now a subsidiary of Bristol-Myers Squibb (BMS), recently built its second production plant in Couvet, followed by the construction of a third production site in Boudry (Neuchâtel), to produce
-
The impact of COVID-19 on clinical trials
Eli Lilly, Bristol-Myers Squibb and Pfizer also have multiple development programmes that are paused or delayed.
More from intelligence
Approximately 4 fully matching, plus 49 partially matching documents found.
Latest appointments
-
Genmab hires first chief operating officer
Anthony Mancini joins from Bristol-Myers Squibb. Biotech company Genmab has appointed Anthony Mancini (pictured above) as executive vice president and to the newly created position of chief operating officer. ... Most recently, he led Bristol-Myers
-
Ex-BMS exec jumps to Gilead to lead research group
Gilead appoints Michael Quigley to lead research team. A former Bristol-Myers Squibb executive has jumped ship to Gilead, where he will head up the company’s research biology group.
-
New hires at FibroGen, Saniona and Turbine
Bristol-Myers Squibb.
-
New hires at Bristol-Myers Squibb, Acceleron and FerGene
The latest movers in pharma. Bristol-Myers Squibb. Bristol-Myers Squibb has announced changes to its leadership team, following the retirement of its current executive vice president of corporate affairs and
-
New faces at Prime Global, Swordfish Advertising and Wilmington Healthcare
Roger Tomlins (pictured right), who joins Wilmington from Bristol-Myers Squibb, has worked in healthcare for over 16 years, in both the pharmaceutical industry and the NHS.
More from appointments
Approximately 10 fully matching, plus 105 partially matching documents found.
Latest from PMHub
-
From Vision to Action: Medical Affairs’ Time to Lead is Now – Key Themes and Takeaways From the 2022 Medical Affairs Professional Society (MAPS) Global Annual Meeting
future. The session titled A Strategic Approach to Revolutionizing Digital Impact for Medical Affairs, presented by Luca Dezzani (Johnson &Johnson), Bora Erdemli (ZS Associates), Stacey Gorski (AstraZeneca), and Shaji Kalathil (Bristol ... Myers Squibb),
-
Claire wins Healthcare Communications Leader at Communiqué 2021
The Excellence in Healthcare Partnerships category for our work with Bristol Myers Squibb.Our team developed a Back-to-Work Guide in partnership with people who have directly experienced, and overcome,
-
Communiqué 2021 – in real life!
In the Excellence in Healthcare Partnerships category, working with Bristol Myers Squibb, our team developed a Back-to-Work Guide in partnership with people who have directly experienced, and overcome, the
-
The key to psoriasis innovation? Dispelling the shadow of the JAK inhibitor
In contrast to many existing treatments for more difficult-to-control forms of psoriasis which are intravenous, TYK2 inhibitors– like Bristol Myers Squibb’s deucravacitinib (BMS-986165) –are being trialed as
-
Clinical trials and the diversity principle
In August, Bristol Myers Squibb announced it was committing $300m to tackle diversity in clinical trials, saying ‘COVID-19 has exposed the severity of social and health disparities in the US
More from PMHub
Approximately 3 fully matching, plus 11 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Country Manager, Healthcare Communications Agency, Germany
-
Highly competitive salary
- Sanofi halts recruitment for trials assessing MS treatment
- bluebird bio reveals plans to launch two gene therapies
- AstraZeneca and Daiichi Sankyo receive FDA approval for lung cancer drug
- ONS data reveals significant decrease in COVID-19 antibodies
- Bristol Myers Squibb and GentiBio in $1.9bn deal to develop IBD therapies
- UK government’s ‘science superpower’ ambitions to fail without clear plan, Lords committee warns
- WHO releases interim statement on COVID-19 vaccination for children and adolescents
- Novartis reports death of two patients treated with Zolgensma
- The impact of COVID-19 on the fight against AMR
- NHS bowel cancer checks reach record-high following death of Dame Deborah James
- Environment: where does the pharmaceutical industry stand?
- Moderna’s Omicron booster receives MHRA approval
- Sanofi halts recruitment for trials assessing MS treatment
- BeiGene announces positive phase 3 trial results for liver cancer treatment
- Amgen acquires ChemoCentryx in $3.7bn cash deal
- A creative awakening – how pharma is bringing innovation to the patient journey
- Superstar congresses and conferences will stay centre stage but now share the limelight with virtual and hybrid events
- AbbVie and Sosei Heptares collaborate in new agreement worth up to $1.2bn
PMHub
Havas Lynx Group
We are the Havas Lynx Group. Devoted to fresh thinking. Changing the way the world does healthcare communications for the...
Latest intelligence
- Environment: where does the pharmaceutical industry stand?
- ...
- The communication challenge of helping he next generation to be healthier
- As the pressure on the health service increases the health of the next generation is vital for everyone. How do we show positive attitudes and change behaviour while future proofing...
- Are we losing sight of what the democratisation of healthcare really looks like?
- We have a core responsibility as healthcare communicators to consistently drive for better inclusion, engagement and compliance. What does the ‘democratisation of healthcare’ really look like?...
